The National Cancer Institute gave Chrysalis BioTherapeutics $1.5 million for the continued development of Chrysalin, a regenerative peptide that could lessen radiotherapy-induced brain tissue damage. In clinical trials involving skin healing and bone repair, adverse events were not reported, said Darrell H. Carney, founder and CEO of Chrysalis.
Institute backs development of drug to protect brain from radiotherapy
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan